Two-year durability of REBYOTA&#8482; (RBL), a live biotherapeutic for the prevention of recurrent <i>Clostridioides difficile</i> infections.

Orenstein, Robert; Hecht, Gail; Harvey, Adam; Tillotson, Glenn; Khanna, Sahil

Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections.

Orenstein, Robert; Hecht, Gail; Harvey, Adam; Tillotson, Glenn; Khanna, Sahil.

Afiliación

Orenstein R; Division of Infectious Diseases, Mayo Clinic, Phoenix, AZ, USA.
Hecht G; Division of Gastroenterology, Hepatology and Nutrition, Loyola University Medical Center, Maywood, IL, USA.
Harvey A; Rebiotix Inc., a Ferring Company, Roseville, MN, USA.
Tillotson G; GST Micro LLC, North, VA.
Khanna S; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Open Forum Infect Dis ; 10(9): ofad456, 2023 Sep.

Article en En | MEDLINE | ID: mdl-37691735

Palabras clave

Clostridioides difficile infection; bile acids; durable response; live biotherapeutic product; microbiome

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Open Forum Infect Dis Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google